176 related articles for article (PubMed ID: 34315295)
1. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort.
Sawhney S; Agarwal M
Lupus; 2021 Oct; 30(11):1829-1836. PubMed ID: 34315295
[No Abstract] [Full Text] [Related]
2. Effectiveness and Safety of Rituximab in Systemic Lupus Erythematosus: A Case Series Describing the Experience of 2 Centers.
Gómez VJ; Carrión-Barberá I; Salman Monte TC; Acosta A; Torrente-Segarra V; Monfort J
Reumatol Clin (Engl Ed); 2020; 16(5 Pt 2):391-395. PubMed ID: 30522941
[TBL] [Abstract][Full Text] [Related]
3. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
4. The retrospective evaluation of efficacy and safety data after switching from originator rituximab to biosimilar rituximab (CT-P10) in patients diagnosed with systemic lupus erythematosus: a single-center experience.
Ekin A; Mısırcı S; Coşkun BN; Yağız B; Dalkılıç E; Pehlivan Y
Eur Rev Med Pharmacol Sci; 2024 May; 28(10):3513-3522. PubMed ID: 38856126
[TBL] [Abstract][Full Text] [Related]
5. Rituximab as add-on therapy in patients with resistant lupus nephritis who have failed induction or maintenance therapy with other agents: A real-world experience from a single center in Mumbai.
Yadav S; Balakrishnan C; Mangat G; Kothari J
Lupus; 2024 Jan; 33(1):88-95. PubMed ID: 38048588
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.
Tambralli A; Beukelman T; Cron RQ; Stoll ML
J Rheumatol; 2015 Mar; 42(3):541-6. PubMed ID: 25593242
[TBL] [Abstract][Full Text] [Related]
7. Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
Reis J; Aguiar F; Brito I
Acta Reumatol Port; 2016; 41(1):45-55. PubMed ID: 27115107
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Rituximab in the Management of Pediatric Systemic Lupus Erythematosus: A Systematic Review.
Mahmoud I; Jellouli M; Boukhris I; Charfi R; Ben Tekaya A; Saidane O; Ferjani M; Hammi Y; Trabelsi S; Khalfallah N; Tekaya R; Gargah T; Abdelmoula L
J Pediatr; 2017 Aug; 187():213-219.e2. PubMed ID: 28602379
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
Jiang B; Li T; Guo L; Shen H; Ye S; Chen S
J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
[TBL] [Abstract][Full Text] [Related]
10. Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE.
Gilbert M; Goilav B; Hsu JJ; Nietert PJ; Meidan E; Chua A; Ardoin SP; Wenderfer SE; von Scheven E; Ruth NM;
Pediatr Rheumatol Online J; 2021 Aug; 19(1):137. PubMed ID: 34461932
[TBL] [Abstract][Full Text] [Related]
11. Rituximab as Maintenance Treatment for Systemic Lupus Erythematosus: A Multicenter Observational Study of 147 Patients.
Cassia MA; Alberici F; Jones RB; Smith RM; Casazza G; Urban ML; Emmi G; Moroni G; Sinico RA; Messa P; Hall F; Vaglio A; Gallieni M; Jayne DR
Arthritis Rheumatol; 2019 Oct; 71(10):1670-1680. PubMed ID: 31102498
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.
Trachana M; Koutsonikoli A; Farmaki E; Printza N; Tzimouli V; Papachristou F
Rheumatol Int; 2013 Mar; 33(3):809-13. PubMed ID: 22101555
[TBL] [Abstract][Full Text] [Related]
13. Rituximab therapy for juvenile-onset systemic lupus erythematosus.
Nwobi O; Abitbol CL; Chandar J; Seeherunvong W; Zilleruelo G
Pediatr Nephrol; 2008 Mar; 23(3):413-9. PubMed ID: 18097688
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.
Ahn YH; Kim SH; Han KH; Choi HJ; Cho H; Lee JW; Shin JI; Cho MH; Lee JH; Park YS; Ha IS; Cheong HI; Kim SY; Lee SJ; Kang HG
Medicine (Baltimore); 2018 Nov; 97(46):e13157. PubMed ID: 30431588
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.
Tanaka Y; Takeuchi T; Miyasaka N; Sumida T; Mimori T; Koike T; Endo K; Mashino N; Yamamoto K
Mod Rheumatol; 2016; 26(1):80-6. PubMed ID: 26054418
[TBL] [Abstract][Full Text] [Related]
17. Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years.
Aguiar R; Araújo C; Martins-Coelho G; Isenberg D
Arthritis Care Res (Hoboken); 2017 Feb; 69(2):257-262. PubMed ID: 27110698
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of an anti-CD20 monoclonal antibody, rituximab, for lupus nephritis: A meta-analysis.
Teng S; Tian Y; Luo N; Zheng Q; Shao M; Li L
Int J Rheum Dis; 2022 Feb; 25(2):101-109. PubMed ID: 34811947
[TBL] [Abstract][Full Text] [Related]
20. Rituximab use as induction therapy for lupus nephritis: a systematic review.
Stolyar L; Lahita RG; Panush RS
Lupus; 2020 Jul; 29(8):892-912. PubMed ID: 32486934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
